The Use of Moxisaxin for Treatment of a Decompensated Cirrhosis Patient with Severe Pulmonary Infection

 Moxifloxacin is recommended for empirical antibiotic treatment of patients with cirrhosis. However, due to a lack of clinical safety data on moxifloxacin in Child-Pugh C patients, it is unknown how to use moxifloxacin in clinical practice.

 A 76-year-old female with decompensated cirrhosis developed pneumonia during hospitalization. She had an initial failure to respond to imipenem/cilastatin + linezolid therapy. After three-day therapy with imipenem/cilastatin + moxisaxin, her infection symptoms rapidly improved. At this time, she presented a poor response with suspected hepatic encephalopathy. Given the worsening clinical symptoms caused by drug hepatotoxicity, moxisaxin was discontinued. Then, her body temperature rapidly raised.

 Moxisaxin may be a potentially useful antibiotic for hospital-acquired pneumonia in patients with decompensated cirrhosis, but further studies are needed to validate its hepatotoxicity.